NYSTATIN ORAL SUSPENSION, USP (100,000 units per mL) Rx only

Manufacturer
Kanchan Healthcare Inc | MLV Pharma LLC | AptaPharma Inc.
Effective date
2026-10-07
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
daily-update
Hydrated at
2026-10-10 01:06:45

Label at a glance#

ProductNYSTATIN
Active ingredientNYSTATIN
Label structure12 sections

Indications and uses

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

Dosage and administration

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes). NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective. CHILDREN AND ADULTS: 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). T...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei.
Structural formula:

image descriptionimage description

Nystatin Oral Suspension, for oral administration, is cherry/mint flavored, containing 100,000 USP Nystatin Units per mL. Inactive ingredients: disodium edetate, sodium benzoate, sodium hexametaphosphate, dibasic sodium phosphate heptahydrate, monobasic sodium phosphate monohydrate, glycerin, methyl paraben, propyl paraben, sucrose, cherry flavor and peppermint oil.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Pharmacokinetics

PHARMACOKINETICS SECTION

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

MICROBIOLOGY SECTION

Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects Category C

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

See DOSAGE AND ADMINISTRATION.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

OVERDOSAGE

OVERDOSAGE SECTION

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see CLINICAL PHARMACOLOGY, Pharmacokinetics).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.

HOW SUPPLIED

HOW SUPPLIED SECTION

Nystatin Oral Suspension, USP, 100,000 USP Nystatin Units per mL, is available as a cherry-mint flavored, yellow, ready-to-use suspension.
60 mL bottles with a 1 mL calibrated dropper
(NDC: 85742-013-10) and 1 Pint
(473 mL) bottles (NDC: 85742-013-11)

SHAKE WELL BEFORE USE

SPL UNCLASSIFIED SECTION

Storage
Store at 20° - 25°C (68° - 77°F); excursions permitted between 15° - 30°C (59° - 86°F) [see USP Controlled Room Temperature]. AVOID FREEZING.

PHARMACIST: Dispense in a tight light-resistant container as defined in USP.

Manufactured for:
Kanchan Healthcare Inc
1 Gatehall Drive; Suite No. 202
Parsippany, NJ 07054 USA

Toll Free Number: 833-845-2624

Rev: 06/2025

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

nystatin 60ml Labelnystatin 60ml Label

nystatin 60ml Cartonnystatin 60ml Carton

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

nystatin 473ml Labelnystatin 473ml Label

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e29fe634-dc25-094c-c77f-5d09c3eceb3eProduct name520260107
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
e57b6340-9387-3f9a-7307-511c81791375Product name320221214
544f8e8d-6389-eeeb-9586-aa447c08dcc7Product name520210614
1629e00f-54fb-4a43-8306-b58442b23902Product name920200430
854ec07b-1cd7-a5db-235a-7aa24d3cf97aProduct name320180628
19b9f4c1-15e9-edcc-4c16-f01ecfb5c549Product name120140508
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
85742-013-10ML - Milliliter85742-01306ea4c79-8f02-4af6-8b21-1b9ff937980b12025-12-16
85742-013-11ML - Milliliter85742-013e963209c-0b03-4094-8082-9232670fbf5f12025-12-16

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
85742-01385742-013-10, 85742-013-11

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
12025-09-12full-release2026-05-31 21:43:35

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062832-001NYSTATINNYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A062832-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-2784e616aacf4f…
2026-08-18 06:07:402026-07A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-2731067a03dcf5…
2025-08-23 18:47 UTC2025-08A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-276a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-2703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-272680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-275bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-2779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-271e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-278072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-275c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-275d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-274b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-2774a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-2787673890dc5c…
2021-03-12 10:30 UTC2021-03A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-275aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-278869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-273f01610625f2…
2019-09-15 20:21 UTC2019-09A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27b00525d2431f…
2019-07-19 19:46 UTC2019-07A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-276a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-271c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-279b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-273f0d92c62455…
2023-05-13 08:27 UTC2023-05A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27053a50430f4f…
2023-01-26 05:58 UTC2023-01A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-273bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-273a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A062832-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A062832-001AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062832-001AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062832-001AA131067a03dcf5…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062832-001AA15bbf6a4d5a75…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062832-001AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062832-001AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062832-001AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062832-001AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062832-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062832-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062832-001AA14b0b4de00fa7…
2022-03-09 01:35 UTC2022-03A062832-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062832-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062832-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A062832-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062832-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062832-001AA1c0c555d07b60…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062832-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062832-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062832-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062832-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062832-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062832-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062832-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A062832-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A062832-001AA13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062832-001AA13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062832-001AA1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A062832-001AA1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A062832-001AA1cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A062832-001AA1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
a7f34e4a-98d2-4cbf-9e62-1a2b5f00bcfd90a52c3f-3ef7-4f3b-9fe5-40af408e9f2a2025-09-12Adverse reactionsExact identifier
spl set id: 90a52c3f-3ef7-4f3b-9fe5-40af408e9f2a

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.